Skip to the content

Why vaping won't stop the long-term decline of 'big tobacco'

30 October 2018

Shane De La Haye, assistant fund manager at Ashburton Investments, considers the rise of vaping and what it means for investors in 'big tobacco' companies.

By Shane De La Haye,

Ashburton Investments

The global cigarette industry has been in decline for the last five years. Cigarette demand peaked in 2012, with around six trillion cigarettes being consumed worldwide. Since then, the volume of consumption has declined by 9.2 per cent (compound annual growth rate -1.9 per cent) to 5.4 trillion cigarettes in 2017. The decline in volume has been driven by a number of factors including rising regulation, higher excise duties, growing consumer health consciousness, as well as the availability of cheaper alternatives.

Smoking rates in the US and UK are currently at their lowest levels in years, at 15.5 per cent and 15.8 per cent respectively, measured as a percentage of total population. Vaping has become a popular alternative for smokers seeking to quit the habit – the cost of maintaining a vaping habit is considerably cheaper than traditional smoking.

The global vape market is currently valued at $22.6bn and is estimated to grow to $61bn by 2025, representing a compound annual growth rate of 15.4 per cent. The US and UK are the leading vape markets globally, with 3.7 per cent and 5.6 per cent of their respective populations using e-cigarettes.

Growth in vaping will benefit global tobacco companies, such as British American Tobacco (BATS) and Philip Morris, as they own many of the largest vape brands. BATS has a 40 per cent market share of the UK vaping market, the second largest vape market globally after the US.

Although BATS have a significant share of the global vaping sector, the vape market is still only a fraction of the size of the traditional cigarette market, where sales totalled nearly $700bn in 2017. The vaping market also remains fragmented, with many participants being small-to-medium sized private companies. Barriers of entry into the market are very low due to the relatively small initial outlay of capital required to produce or supply the liquids and devices.

The substantial cost savings afforded by vaping have been a major driver of its popularity in recent years. However, vape products are not currently taxed in the same way as tobacco products. If governments decide to apply a similar level of excise tax to vape products, there is a risk that vaping margins will deteriorate if the additional costs are not passed on to the consumers.

BATS do not currently disclose the financial performance of the vaping business, which we estimate to be loss-making currently.

As the vape market has expanded, so has product regulation and questions on nicotine content-based taxes. In 2016, the US Food and Drug Administration (FDA) extended its regulatory power to include e-cigarettes, which it deemed to be tobacco products. Regulation on vaping varies from country to country, with some countries having no regulation whatsoever, and others banning vape devices and liquids altogether.

Some Asian countries such as Japan and Thailand have banned the sale and use of liquids containing nicotine, which has led to the increased adoption of ‘Heat not Burn’ (HnB) tobacco devices, particularly in Japan. As regulation surrounding vaping evolves, so will the vape market and its constituents, along with the risk that profits will erode further should excise duties be imposed or if vape product advertising is banned.

Vape products have only been available to the mass market for a relatively short time, meaning the long-term health risks or benefits are still unknown. While vaping ‘smoke’ does not produce many of the harmful substances contained within tobacco smoke, such as tar or carbon monoxide, it does still contain nicotine, which remains a highly addictive and regulated substance in most countries.

Numerous studies have been conducted to determine how much safer vaping really is when compared to smoking tobacco. The majority of studies concluded vaping lowers the number of toxins and carcinogens ingested, in comparison to smoking or chewing tobacco. As a result, many health bodies, including the UK’s NHS, have recommended vaping as a way to quit smoking. They state that although vaping is not completely risk-free, it carries a lower risk than smoking conventional cigarettes.

As and when vaping becomes more mainstream, the regulation surrounding the products will be increased. Whether those additional costs of adherence will be passed down to the customers, is yet to be determined.

The rapid growth of the vaping industry has been a double-edged sword for large tobacco companies. On one hand, the popularity of vaping has provided much needed growth within the industry, but at a cost, given the margin dilution. Rising demand for vaping has also resulted in cannibalisation from the traditional cigarette businesses, exacerbating the size and speed of volume declines within factory made cigarettes. As a result, we do not expect the rising demand for vaping to arrest the long-term decline in the global tobacco industry.

Shane De La Haye is an assistant fund manager at Ashburton Investments. The views expressed above are his own and should not be taken as investment advice.

Editor's Picks

Loading...

Videos from BNY Mellon Investment Management

Loading...

Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.